glp-1 receptor agonist news drugs promise wider health benefits, but experts urge caution on use A clinician's perspective ๐ GLP-1
Description
NCT02970942 results [2] Among patients treated with semaglutide, those in the 0.4 mg group experienced an average weight loss of 13%, compared to 1% in the placebo group
Incretin-Based Therapy and Type 2 Diabetes
A statistically significant improvement in fibrosis was also observed
Challa TD, Beaton N, Arnold M, Rudofsky G, Langhans W, Wolfrum C
